Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470
Journal
Anti-Cancer Drugs
Journal Volume
13
Journal Issue
7
Pages
743-749
Date Issued
2002
Author(s)
Abstract
We have previously shown that C-CAM1-based gene therapy effectively suppressed prostate tumor growth in nude mice xenograft models. In this study, we examined the effects of combining C-CAM1-based therapy and TNP-470, a potent angiogenesis inhibitor, on prostate cancer in a xenografted tumor model. The direct cytotoxic effects of Ad-C-CAM1 (recombinant adenovirus containing C-CAM1 cDNA) and TNP-470 on DU145 cells in vitro were determined by microculture tetrazolium assay. The in vivo antitumor effects of either agent alone were studied in a DU145 xenografted tumor model. Cells were infected with Ad-C-CAM1 or the control virus at multiplicities of infection (m.o.i.) of 5 or 10 and then inoculated onto nude mice 48 h later. TNP-470 (0,17 or 35 mg/kg) was given 15,17 and 19 days after inoculation. Combined treatments in vivo were carried out to determine whether there were synergistic antitumor effects. Both Ad-C-CAM1 and the control virus were minimally toxic to DU145 in vitro. There was evident dose-dependent suppression of xenografted tumor growth by either Ad-C-CAM1 or TNP-470. By the median-effect analysis, combination of the two agents generated strong synergistic antitumor effects as shown by marked tumor suppression as compared to either treatment alone. The novel strategy may have clinical implications for the treatment of prostate cancer. ? 2002 Lippincott Williams & Wilkins.
Subjects
Cell adhesion molecule; Gene therapy; Prostatic neoplasms; Tumor suppressor; Xenograft
SDGs
Other Subjects
adenovirus vector; cell adhesion molecule; cell cell adhesion molecule 1; fumagillol chloroacetylcarbamate; unclassified drug; adenosine triphosphatase; angiogenesis inhibitor; carcinoembryonic antigen; CD66 antigens; Ceacam1 protein, mouse; Ceacam2 protein, mouse; cell adhesion molecule; cyclohexane derivative; fumagillol chloroacetylcarbamate; glycoprotein; leukocyte antigen; O-(chloroacetylcarbamoyl)fumagillol; sesquiterpene; angiogenesis; animal experiment; animal model; animal tissue; antineoplastic activity; article; assay; controlled study; cytotoxicity; dose response; drug potentiation; gene therapy; growth inhibition; in vitro study; in vivo study; inoculation; male; mouse; nonhuman; priority journal; prostate cancer; tumor growth; tumor regression; tumor suppressor gene; tumor volume; virus recombinant; xenograft; animal; Bagg albino mouse; cell culture; cell survival; drug effect; genetics; multimodality cancer therapy; nude mouse; pathology; prostate tumor; Adenosinetriphosphatase; Angiogenesis Inhibitors; Animal; Cell Adhesion Molecules; Cell Survival; Combined Modality Therapy; Dose-Response Relationship, Drug; Gene Therapy; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prostatic Neoplasms; Sesquiterpenes; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.; Tumor Cells, Cultured; Adenosine Triphosphatases; Animals; Antigens, CD; Carcinoembryonic Antigen; Cell Survival; Combined Modality Therapy; Cyclohexanes; Dose-Response Relationship, Drug; Glycoproteins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Tumor Cells, Cultured
Type
journal article